LUCID DIAGNOSTICS INC.
Lucid Diagnostics Inc (LUCD) is a small-cap clinical diagnostics company that develops and commercialises diagnostic tests and related technologies. Investors should know it operates in the healthcare diagnostics space, where product development, regulatory approvals and commercial rollout are key value drivers. The company’s market capitalisation is around $166 million, which places it in the small‑cap category and can mean higher price volatility and liquidity risk. Potential opportunities include market demand for rapid and accurate diagnostics and partnerships with larger healthcare companies. Key risks include clinical and regulatory setbacks, reimbursement challenges, competition from established diagnostics players and typical small‑company funding needs. This summary is for general educational purposes and not investment advice; investors should perform further research, check regulatory filings and consider whether a small‑cap diagnostics stock suits their risk profile.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lucid Diagnostics stock, expecting it to rise significantly in value.
Financial Health
Lucid Diagnostics is generating modest revenue and cash flow, indicating stable but limited financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LUCD
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap dynamics
Smaller market capitalisation can mean faster growth potential but also greater share price swings and lower liquidity; suitable only for risk‑tolerant investors.
Technology & approvals
Progress depends on product development and regulatory milestones, which can materially affect outlook—both upside and downside are possible.
Market adoption factors
Commercial adoption, reimbursement and partnerships influence long‑term prospects; performance can vary across regions and payor systems.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
